From Alchemy To Ipo Book in PDF, ePub and Kindle version is available to download in english. Read online anytime anywhere directly from your device. Click on the download button below to get a free pdf file of From Alchemy To Ipo book. This book definitely worth reading, it is an incredibly well-written.
Written by a well-known industry insider, this title addresses the coming-of-age of biotech products and companies and traces the history of biotechnology from its early inception in the '70s to today's heyday of new solutions and breakthrough treatments.
The Race to Commercialize Biotechnology by Steven Collins Pdf
This comparative study looks at the early development of biotechnology in the US and Japan. Drawing on primary and secondary sources it traces the historical roots of recombinant DNA technology, discusses the tensions between regulation and promotional policies and identifies the major actors and strategies that launched biotechnology in both countries. Developing several strands of theory in economic history, science and technology policy, the book proposes a simple model that relates the differences in the two countries' responses to variations in the availability of institutional, financial and organizational resources needed to commercialize the new technology.
Science, the State and the City by Geoffrey Owen,Michael M. Hopkins Pdf
The book examines the evolution of one of the most important technologies that has emerged in the last fifty years: biotechnology - the use of living organisms, or parts thereof to create useful products and services. The most important application of biotechnology has been in medicine, in the development of new drugs. The central purpose of the book is to explain how firms based in the US took the lead in commercialising the technology, and why it has been so difficult for firms in other countries to match what the leading American companies have achieved. The book looks at the institutions and policies which have underpinned US success in biotechnology. This is the US innovation "ecosystem," and it is made up of several interlocking elements which constitute a powerful competitive advantage for US biotechnology firms. These include, a higher education system which has close links with industry, massive support from the Federal government for biomedical research, and a financial system which is well equipped to support young entrepreneurial firms in a science-based industry. In the light of US experience the book examines in detail the performance of UK biotechnology firms over the past forty years, starting with the creation of the UK's first dedicated biotech firm, Celltech, in 1980. The book shows how the UK made a promising start in the 1980s and 1990s but failed to build on it. Several leading firms failed, and after an initial burst of enthusiasm investors lost confidence in the British biotech sector. It is only the last few years that the sector has staged a revival, attracting fresh investment from the US as well from the UK. The story told in this book, based on extensive interviews with industry participants, investors, and policy makers in the UK, Continental Europe, and the US, sheds new light on one of the central issues facing governments in the advanced industrial countries - how to create and sustain new science-based industries.
Biocapital is a major theoretical contribution to science studies and political economy. Grounding his analysis in a multi-sited ethnography of genomic research and drug development marketplaces in the United States and India, Kaushik Sunder Rajan argues that contemporary biotechnologies such as genomics can only be understood in relation to the economic markets within which they emerge. Sunder Rajan conducted fieldwork in biotechnology labs and in small start-up companies in the United States (mostly in the San Francisco Bay area) and India (mainly in New Delhi, Hyderabad, and Bombay) over a five-year period spanning 1999 to 2004. He draws on his research with scientists, entrepreneurs, venture capitalists, and policymakers to compare drug development in the two countries, examining the practices and goals of research, the financing mechanisms, the relevant government regulations, and the hype and marketing surrounding promising new technologies. In the process, he illuminates the global flow of ideas, information, capital, and people connected to biotech initiatives. Sunder Rajan’s ethnography informs his theoretically sophisticated inquiry into how the contemporary world is shaped by the marriage of biotechnology and market forces, by what he calls technoscientific capitalism. Bringing Marxian theories of value into conversation with Foucaultian notions of biopolitics, he traces how the life sciences came to be significant producers of both economic and epistemic value in the late twentieth century and early twenty-first.
This book deals with the rapid changes in contemporary molecular biology, particularly genome sciences, and the manner in which they can be understood through the lens of political economy. Specifically, the work investigates the case of the United States-led Genome Project (HGP), in order to show that even large-scale basic science is closely bound up in the progression of capitalist social relations. The work has, in part, been motivated by the lack of rigorous analysis of the HGP. Most the existing literature tends to present either a chronological review of events surrounding the HGP or describe it thematically. In contrast, this book contributes to a needed discussion concerning the 'why and how' of the HGP emergence. It elucidates the features within capitalist social relations which have simultaneously enable the HGP and ensure its amenability to systemic demands. The work's most compelling elements are both historical and analytical. Historically, it places the HGP within the context of wider political, economic and social issues. Related to this, it puts forward an analytical, explanatory understanding of the project's emergence, making it a valuable tool for both political economists, science & society theorists, and even bioethicists.
Author : Victor Roy Publisher : Univ of California Press Page : 216 pages File Size : 54,7 Mb Release : 2023-01-24 Category : Medical ISBN : 9780520388727
A free open access ebook is available upon publication. Learn more at www.luminosoa.org. Capitalizing a Cure takes readers into the struggle over a medical breakthrough to investigate the power of finance over business, biomedicine, and public health. When curative treatments for hepatitis C launched in 2013, sticker shock over their prices intensified the global debate over access to new medicines. Weaving historical research with insights from political economy and science and technology studies, Victor Roy demystifies an oft-missed dynamic in this debate: the reach of financialized capitalism into how medicines are made, priced, and valued. Roy’s account moves between public and private labs, Wall Street and corporate board rooms, and public health meetings and health centers to trace the ways in which curative medicines became financial assets dominated by strategies of speculation and extraction at the expense of access and care. Provocative and sobering, this book illuminates the harmful impact of allowing financial markets to determine who heals and who suffers and points to the necessary work of building more equitable futures.
A Philosopher on Wall Street by David Ewing Duncan Pdf
An astonishing tale of Wall Street and the explosion of new life-science technologies and other industries of the future as told by one of the most creative dealmakers of the past 60 years. When Fred Frank arrived on Wall Street in 1958, he became a key member of a small, whip-smart cadre of young financiers who began challenging the stodgy, risk-averse scions of old-world investment banking. He also became the first banker to specialize in biotechnology, pharmaceuticals, and health care services. Frank’s perpetual search for the new—pioneering technologies and innovative business models—has transformed our world. A Philosopher on Wall Street is an intriguing tale of • a man who was a force of verve and ingenuity on Wall Street, who built and nurtured new industries that have impacted everyone; • Wall Street and its history since the late 1950s, the surprisingly fascinating story of how high technology in America was capitalized, and the formation and meteoric rise of the pharma and biotech industries; • the best and worst of Wall Street over the past sixty years, and thoughts about the future of how to fund innovation to benefit both people and the bottom line • colorful stories from top innovators, scientists, executives, and investors about deals, intrigue, genius, booms and busts. This is the story of one of the most creative dealmakers of the past sixty years, a master artist of finance whose erudition and grace helped shape our world, who has always believed that inspired science, entrepreneurship, and investing are the keys to a better future.
Biotechnology Organizations in Action by J. Norus Pdf
This volume analyzes the dynamics and interactive processes among the players (individuals, institutions, and organizations/firms) that have constituted and legitimized the development of the biotechnology industries. The unit of analysis is small entrepreneurial firms developing biotechnological products and processes. What types of strategies are small entrepreneurs pursuing in order to create markets for their new products and processes, and how have specific strategies emerged? The primary interest is the network process through which the technological field and the development of institutions and routines evolve and co-evolve. The theoretical contribution of the book is its focus on the development of the concept of networks. From being regarded as a relative static concept the book transforms the concept into a dynamic concept of networking. The dynamic view on the creation and development of new technologies through network formations is linked to the concept of strategy that is used throughout the book. Hence the strategies are developed along with the creation of technological knowledge, and it is hoped that the diffusion of this specific knowledge will bring new actors into the technological arena or community. This book will be useful to the academic community, those studying the formation of networks, strategic management, organizational behavior, and management of technology, as well as business observers with a specific interest in the evolution of the biotechnology industry.
"The Biotech Investor's Bible" ist der maßgebliche Leitfaden für die Geldanlage in die zunehmend beliebteren, aber außerordentlich schwankungsanfälligen Biotechnologiewerte. Dieses einzigartige Buch erklärt die Grundlagen von Genetik, Patenten und Therapien und zeigt dem Anleger, wie er Biotechnologieunternehmen, deren Spitzentechnologie und neuesten Produkte bewertet. "The Biotech Investor's Bible" bietet eine interessante Zusammenfassung der relativ kurzen Geschichte dieses Industriezweiges und vermittelt einen umfassenden Überblick über verschiedene Branchenbereiche. Technologie und Wissenschaft des Biotechnologiemarktes werden zusammen mit detaillierten Investmentstrategien ausführlich erläutert. Autor George Wolff ist ein erfahrener Experte auf diesem Gebiet. "The Biotech Investor's Bible" ist eine unverzichtbare Lektüre für aktuelle und künftige Biotech-Anleger.
Author : Eric J. Vettel Publisher : University of Pennsylvania Press Page : 291 pages File Size : 55,9 Mb Release : 2013-03-01 Category : History ISBN : 9780812203622
The seemingly unlimited reach of powerful biotechnologies and the attendant growth of the multibillion-dollar industry have raised difficult questions about the scientific discoveries, political assumptions, and cultural patterns that gave rise to for-profit biological research. Given such extraordinary stakes, a history of the commercial biotechnology industry must inquire far beyond the predictable attention to scientists, discovery, and corporate sales. It must pursue how something so complex as the biotechnology industry was born, poised to become both a vanguard for contemporary world capitalism and a focal point for polemic ethical debate. In Biotech, Eric J. Vettel chronicles the story behind genetic engineering, recombinant DNA, cloning, and stem-cell research. It is a story about the meteoric rise of government support for scientific research during the Cold War, about activists and student protesters in the Vietnam era pressing for a new purpose in science, about politicians creating policy that alters the course of science, and also about the release of powerful entrepreneurial energies in universities and in venture capital that few realized existed. Most of all, it is a story about people—not just biologists but also followers and opponents who knew nothing about the biological sciences yet cared deeply about how biological research was done and how the resulting knowledge was used. Vettel weaves together these stories to illustrate how the biotechnology industry was born in the San Francisco Bay area, examining the anomalies, ironies, and paradoxes that contributed to its rise. Culled from oral histories, university records, and private corporate archives, including Cetus, the world's first biotechnology company, this compelling history shows how a cultural and political revolution in the 1960s resulted in a new scientific order: the practical application of biological knowledge supported by private investors expecting profitable returns eclipsed basic research supported by government agencies.
Clusters, Networks and Innovation by Stefano Breschi,Franco Malerba Pdf
Examining the role of the much-vaunted concepts of regional clusters in the prosperity and economic expansion of countries, this work looks at the different experiences of industrial districts and high-tech regions such as Silicon Valley, Boston's biotech region, and Hsinchu-Taipei.
A new version of capitalism, grounded in technology and science, is spawning new forms of corporate power and organization that will have major implications for the twenty-first century. Technological creativity is thereby turned into a commodity in new corporate regimes that are primarily oriented toward research and intellectual appropriation. This phenomenon is likely to have major social, economic, and political consequences, as the new corporatism becomes ever more intrusive and rapacious through its control over technology and innovation. In his provocative book Technocapitalism, Luis Suarez-Villa addresses this phenomenon from the perspective of radical political economy and social criticism. Grounded in the premise that relations of power influence how human creativity and technology are exploited by the new corporatism, the author argues that new forms of democratic participation and resistance are needed, if the social pathologies created by this new version of capitalism are to be checked. Considering the new sectors affected by technocapitalism, such as biotechnology, nanotechnology, bioinformatics, and genomics, Suarez-Villa deciphers the common threads of power and organization that drive their corporatization. These new sectors, and the corporate apparatus set up to extract profit and power through them, are imposing standards, creating business models, molding social governance, and influencing social relations at all levels. The new reality they create is likely to affect most every aspect of human existence, including work, health, life, and nature itself.
Entrepreneurship, Innovation, and Platforms by Jeffrey Furman,Annabelle Gawer,Brian S. Silverman,Scott Stern Pdf
Despite recent advances in our understanding of how innovation and entrepreneurship impact the creation and appropriation of value, numerous questions remain unanswered. This volume draws together scholars working at the forefront of entrepreneurship-, strategy-, and innovation-related domains to explore these questions.
This title examines the history of biotechnology when it was new, especially when synonymous with recombinant DNA technology. It focuses on the academic community in the San Francisco Bay Area where recombinant DNA technology was developed and adopted as the first major commercial technology for genetic engineering at Stanford in the 1970s. The book argues that biotechnology was initially a hybrid creation of academic and commercial institutions held together by the assumption of a positive relationship between private ownership and the public interest.
